SUMMARY.-l. Mice 4. 5-Methyltetrahydrofolic acid and citrovorum factor did not differ greatly in their ability to inhibit methotrexate toxicity. It is suggested that the pharmaceutical effects of citrovorum factor are due to its conversion to 5-methyltetrahydrofolic acid.
ALTHOUGH methotrexate is a powerful inhibitor of malignant cell growth its clinical use is restricted by its toxicity, the dose required for complete destruction of the malignant cells usually being sufficient to destroy the host. Attempts have beet made to improve its clinical effectiveness by using agents and modes of treatment which reduce the overall lethal effects while retaining the tumour inhibitory properties. Of these, citrovorum factor (folinic acid; 5-formyltetrahydrofolic acid; 6, 7, has proved the most useful. Combinations of large doses of methotrexate and citrovorum factor give improved survival rates in leukaemic mice (Goldin, Venditti, Kline and Mantel, 1966) and appear advantageous in the treatment of human tumours (Schwarzenberg et al., 1969) . Citrovorum factor is also used as an antidote for methotrexate poisoning. The main storage form of folates in the body being 5-methyltetrahydrofolic acid (Blakley, 1969) , it was anticipated that this compound would have similar protective properties.
The cytotoxic effects of methotrexate have been previously studied by Rueckert and Mueller (1960) and O'Brien (1962) . The conversion of deoxyuridylate to thymidylate (for incorporation into DNA) utilises methylenetetrahydrofolate, and the repletion of this pool of folate requires the production of tetrahydrofolic acid by dihydrofolic acid reductase (Fig. 1) . Methotrexate irreversibly inhibits the reduction of dihydrofolic acid and thus depletes the cell store of tetrahydrofolic acid. This inhibits synthesis of DNA since methylation of deoxyuridylate to thymidylate no longer occurs (Osborn, Freeman and Huennekens, 1958; O'Brien, 1962) . Since tetrahydrofolic acid is also converted (Fig. 2) to lO-formyltetrahydrofolic acid which is required for purine biosynthesis, the cellular synthesis of these compounds is also reduced (Blakley, 1969; Borsa and Whitmore, 1969 The citrovorum factor can enter the folate metabolic cycle directly without prior reduction by dihydrofolic acid reductase. Several routes are possible, but no evidence is yet available to decide which are used. In all routes citrovorum factor is converted to the 5,10-methenyl compound (Fig. 2, I ). This is reduced (II) to 5,10-methylenetetrahydrofolic acid which is then available for the methylation of deoxyuridylate (Fig. 1) . The 5,10-methylene compound may be further reduced (Fig. 2, III) to 5-methyltetrahydrofolic acid, which can be converted (IV) to tetrahydrofolic acid by vitamin B12 demethylation. 5,10-Methenyltetrahydrofolic acid is also hydrolysed (V) to 10-formyltetrahydrofolic acid, which loses the formyl group in purine biosynthesis (VI) forming tetrahydrofolic acid (Blakley, 1969) .
Irrespective of the route followed, citrovorum factor maintains the cell store of tetrahydrofolates without utilisation of the dihydrofolic acid reductase pathway, and thus allows synthesis of DNA and purines in a cell in which the normal route is blocked by methotrexate. The effect of the citrovorum factor will be the same whether it is administered before or after methotrexate. This bypassing of dihydrofolic acid reductase probably accounts for the reversal of the toxic effects of methotrexate by the citrovorum factor.
A convenient synthesis of DL-5-methyltetrahydrofolic acid in good yield now being available (Blair and Saunders, 1970) , its effect on methotrexate toxicity in mice has been studied. Since 5-methyltetrahydrofolic acid replenishes the tetrahydrofolate store within the cell by only one route (Fig. 2, IV) , the relative efficiencies of citrovorum factor and 5-methyltetrahydrofolic acid have also been compared to elucidate the mode of action of the former.
EXPERIMENTAL (fomnpounds
Mifethotrexate. For experiments i and ii (Table I ) methotrexate sodium parenteral (Lederle Laboratories Division) was used after dilution to the appropriate concentrations of methotrexate and NaCl. Subsequently, pure methotrexate dihydrate (Lederle) was added to 0 9 per cent NaCl and dissolved by adding the minimum amount of solid NaHCO3 (final pH approximately 8). Small amounts of residual gelatinous material noticed in some samples were removed by filtration or centrifugationi.
DL-5-Methyl-5,6,7,8-tetrahydrofolic acid.-This was synthetic material (Blair and Saunders, 1970) which for the first tests was only available as the barium salt (MTHF-Ba in tables). After this the calcium salt (MTHF-Ca) was employed instead. Both were administered within an hour of dissolution in 0 9 per cent NaCl.
Citrovorum factor.-This was used as a fresh solution of the calcium salt (calcium leucovorin, Lederle) in 0 9 per cent NaCl.
All test solutions were administered subcutaneously with the dose per kg. bodyweight dissolved in 10 ml., i.e. the volume injected was 0Q3 ml. per 30 g. mouse. Control mice received the same volume of saline solution.
Animnals
Male C57BL/Bcr X IF/Bcr F1 hybrid mice were used throughout. They were lhoused in plastic (" Perspex ") boxes each containing 4 mice, and were fed cube diet 41B and tap water ad libitum.
Groups comprised 8 mice, each weighing 27-29 g. at the time of the first injections. They were weighed several times before starting the experiments, and daily during the experiments. Deaths were also recorded daily. All mice which survived beyond day 11 recovered, and were killed 2-3 weeks after the last injections.
In all experiments methotrexate was administered on 5 consecutive afternoons (days 1-5), and the test compounds were injected 5 hours earlier into the opposite flanks of the animals. The dosages and results obtained are summarised in Table I . In some experiments (Table II) 6,7,7,7,7,7,8,8. 8 0 .6, 7, 7, 7, 7, 7, 8,8. 9 3 . 7,8,8,8,8 . 5 8 .
. . 7,7,7,7,7,7,7,8. 8 2 . 7, 8, 8, 9, 9 Comparison of inhibitory effect with citrovorum factor Direct comparisons have been made between the inhibitory effects of 5-methyltetrahydrofolic acid and citrovorum factor, each administered as the calcium salt under the same conditions.
The first comparison (TableI, iv) indicated that the 5-methyl compound afforded the mice appreciably less protection than did the same dose of citrovorum factor. Experiment vi, using large doses of inhibitors and methotrexate, led to a similar conclusion when based on the number of mice surviving, though at the two higher levels of inhibitor deaths occurred 1-2 days earlier in citrovorum-treated mice. With very small levels of inhibitor (0.37 mg. per kg.; expt. v) 5-methyltetrahydrofolic acid was slightly more effective than citrovorum factor.
It is concluded that these two 5-substituted tetrahydrofolic acids do not differ greatly in their ability to counteract the toxicity of methotrexate under the conditions used here.
Effect of less frequent 5-methyltetrahydrofolic acid injections
In some further experiments the inhibitory effect of a single injection, or of three consecutive daily injections, of this compound has been investigated.
The first test (Table II, 4, 5, 6 . 50 . 1 . 6, 7, 7, 7, 7,7,7 . 5.5 15 . 5, 6,7 . 50 .
0
. 6, 6, 6, 6, 7, 7,7,8 . 9 trexate per kg., the same total amount of inhibitor given on day 5 only had very little protective effect. Even with the dose of inhibitor increased to 50 mg. per kg.
(ii) the protective effect was still small; the maximum survival (3/8) occurred with administration on day 3. With three consecutive daily doses of 15 mg. per kg. (iii), the protective effect of 5-methyltetrahydrofolic acid was greatest (5/8 survivors) when given on days 3, 4 and 5 of methotrexate administration. Injections starting on days 1, 2, 4 or 5 failed to save more than 1 out of 8 animals.
Reduction in the frequency of 5-methyltetrahydrofolic acid administration thus greatly reduces its protective effect against methotrexate toxicity.
DISCUSSION
The highest dihydrofolic acid reductase levels in the mouse, found in the liver, kidney and intestinal mucosa, are under 10-6 moles per kg. body-weight (Werkheiser, 1961) . Methotrexate binds stoichiometrically to the enzyme (Werkheiser, 1961) , and each single daily dose of methotrexate at 20 mg. (about 5 x 10-5 moles) per kg. therefore greatly exceeds the enzyme equivalent with consequent deactivation of tissue dihydrofolic acid reductase.
The above experiments have shown that relatively small daily amounts of 5-methyltetrahydrofolic acid give complete protection, as judged by survival and body-weight, against lethal doses of methotrexate (Table I, i, ii, iii) . This protective action is attributed to direct conversion and utilisation of the 5-methyl compound without involvement of dihydrofolic acid. It also indicates that methotrexate-resistant normal and malignant rat cells owe their resistance to the large amounts of 5-methyltetrahydrofolic acid which they contain (Sotobayashi, Rosen and Nichol, 1966) .
With larger doses of methotrexate the protective effect of small doses of 5-methyltetrahydrofolic acid was reduced or abolished (Table I , iii), but was restored to some extent with increased doses of the 5-methyl compound (vi). This may indicate competition between 5-methyltetrahydrofolic acid and methotrexate for an enzyme, or for a transport mechanism across cell walls such as that demonstrated for methotrexate, folic acid, citrovorum factor and 5-methyltetrahydrofolic acid in the L1210 leukaemic cell (Goldman, Lichtenstein and Oliverio, 1968; Goldman, 1969; Lichtenstein, Oliverio and Goldman, 1969) .
Delayed doses of 5-methyltetrahydrofolic acid afforded considerably reduced protection. A single dose of 50 mg. per kg. resulted in a maximum of 3/8 survivors when administered on day 3 to mice given 5 daily doses of methotrexate at 50 mg. per kg. (Table II , ii). Three consecutive daily doses of 15 mg. per kg. gave most protection (5/8 survivors) when given on days 3, 4 and 5 of methotrexate administration (Table II, iii) .
When citrovorum factor and 5-methyltetrahydrofolic acid were compared in their ability to reverse the toxicity of methotrexate there appeared to be little difference (Table I, iv, v, vi) , suggesting that they both act by a common pathway. Since citrovorum factor may be converted to 5-methyltetrahydrofolic acid (Fig. 2,  I -III) but not vice versa, its pharmaceutical effects are probably due to this conversion.
Preliminary experiments in mice bearing the R1 lymphoma have been kindly carried out by Dr. T. A. Connors of the Chester Beatty Research Institute. These have shown that large doses of 5-methyltetrahydrofolic acid do not affect growth of the tumour, and that, at doses of methotrexate at which the animal succumbs to drug toxicity, combinations of methotrexate and 5-methyltetrahydrofolic acid give improved survival times. Further experiments are in progress.
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